Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
VRTX Vertex Pharmaceuticals Incorporated
JOURNAVX is a non-opioid pain management therapy, aligning with the non-opioid pain management investable theme.
$116.78B
$455.33
-0.44%
VTRS Viatris Inc.
Pipeline includes non-opioid pain management options (e.g., fast-acting meloxicam) as growth drivers.
$12.74B
$11.00
+2.23%
AXSM Axsome Therapeutics, Inc.
Symbravo's non-opioid analgesic profile supports Non-Opioid Pain Management as a broader category.
$7.45B
$149.23
+0.80%
ATRC AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
$1.98B
$40.15
+2.29%
LXRX Lexicon Pharmaceuticals, Inc.
Pilavapadin is a non-opioid pain management therapy in development for neuropathic pain, constituting a non-opioid analgesic product category.
$508.76M
$1.40
-1.76%
ANIK Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
$138.41M
$9.54
+0.58%
SCLX Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
$133.20M
$19.81
+2.11%
ASRT Assertio Holdings, Inc.
INDOCIN, SPRIX, and CAMBIA represent non-opioid analgesics, supporting the Non-Opioid Pain Management theme.
$73.86M
$0.76
-2.67%
GRCE Grace Therapeutics, Inc.
GTx-101.00 is a non-narcotic topical analgesic in development for PHN, supporting the 'Non-Opioid Pain Management' theme.
$44.53M
$3.26
-0.61%
CPIX Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
$35.75M
$2.36
+0.43%
MIRA MIRA Pharmaceuticals, Inc.
The company's pain therapies are non-opioid analgesics, placing them under 'Non-Opioid Pain Management'.
$27.84M
$1.45
-2.03%
APUS Apimeds Pharmaceuticals US, Inc
Apitox functions as a non-opioid analgesic for pain management, aligning with the Non-Opioid Pain Management investable theme.
$26.91M
$2.06
-8.85%

Loading company comparison...

Loading research report...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks